Cerebrovascular Disorders Associated with Ph-Negative Myeloproliferative Diseases

MYELOID TUMORS , , , , ,

MM Tanashyan1, PI Kuznetsova1, AL Melikyan2, AA Raskurazhev1

1 Research Center of Neurology, 80 Volokolamskoe sh., Moscow, Russian Federation, 125367

2 National Medical Hematology Research Center, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

For correspondence: Polina Igorevna Kuznetsova, MD, PhD, 80 Volokolamskoe sh., Moscow, Russian Federation, 125367; Tel.: +7(495)490-24-05, +7(926)142-46-48; e-mail: angioneurology0@gmail.com

For citation: Tanashyan MM, Kuznetsova PI, Melikyan AL, Raskurazhev AA. Cerebrovascular Disorders Associated with Ph-Negative Myeloproliferative Diseases. Clinical oncohematology. 2019;12(4):398–405 (In Russ).

DOI: 10.21320/2500-2139-2019-12-4-398-405

ABSTRACT

Background. Cerebrovascular disorders continue to be among the most common and socially significant worldwide. Among multiple reasons for circulatory disturbances special importance is attached to hemorheology and hemostasis disorders occurring also in patients with Ph-negative myeloproliferative diseases (MPD).

Aim. To investigate typical characteristics of the course of cerebrovascular disorders in patients with Ph-negative MPD.

Materials & Methods. The trial included 169 adult patients with neurological diseases. Among them the main group consisted of 104 patients aged 34 to 55 years (median 48.5 years) with Ph-negative MPD diagnosed at the National Medical Hematology Research Center. The control group consisted of 65 patients aged 51 to 58 years (median 55.5 years) with cerebrovascular diseases without concomitant hematological pathology.

Results. The incidence of acute ischemic strokes was 26.2 % in polycythemia vera (PV), 20.5 % in essential thrombocythemia (ET), and 8.7 % in primary myelofibrosis (PMF).

Conclusion. An acute ischemic stroke with a concurrent thrombotic occlusion of one of the major head arteries is a criterion for ruling out Ph-negative MPD. To identify cerebral lesions in patients with Ph-negative MPD (PV, ET, PMF) MRI of the brain is recommended.

Keywords: cerebrovascular diseases, myeloproliferative diseases, thrombotic complications, hemorheology, hemostasis, ischemic stroke.

Received: February 13, 2019

Accepted: September 8, 2019

Read in PDF

REFERENCES

  1. Верещагин Н.В. Ангионеврология: гетерогенность ишемических нарушений мозгового кровообращения. В кн.: АМН СССР 60-я сессия. Л., 1990. С. 69–71.

    [Vereshchagin NV. Vascular neurology: heterogeneity of ischemic stroke. In: AMN SSSR 60-ya sessiya. (Academy of Medical Sciences of the USSR, the 60th session.) Leningrad; 1990. pp. 69–71. (In Russ)]

  2. Суслина З.А., Верещагин Н.В., Пирадов М.А. Подтипы ишемических нарушений мозгового кровообращения: диагностика и лечение. Consilium medicum. 2001;3(5):218–21.

    [Suslina ZA, Vereshchagin NV, Piradov MA. Subtypes of ischemic stroke: diagnosis and treatment. Consilium medicum. 2001;3(5):218–21. (In Russ)]

  3. Танашян М.М. Гемостаз, гемореология и атромбогенная активность сосудистой стенки в ангионеврологии. Анналы клинической и экспериментальной неврологии. 2007;1(2):29–33.

    [Tanashyan MM. Hemostasis, hemorheology and non-thrombogenic activity of vessel walls in vascular neurology. Annaly klinicheskoi i eksperimental’noi nevrologii. 2007;1(2):29–33. (In Russ)]

  4. Меликян А.Л., Туркина А.Г., Абдулкадыров К.М. и др. Клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз). Гематология и трансфузиология. 2014;59(4):31–56.

    [Melikyan AL, Turkina AG, Abdulkadyrov KM, et al. Clinical recommendations for the diagnosis and therapy of Ph-negative myeloproliferative diseases (polycythemia vera, essential thrombocythemia, primary myelofibrosis). Gematologiya i transfuziologiya. 2014;59(4):31–56. (In Russ)]

  5. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51. doi: 10.1182/blood-2009-03-209262.

  6. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. doi: 10.1182/blood-2016-03-643544.

  7. Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128–33. doi: 10.1182/blood-2012-07-444067.

  8. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755–61. doi: 10.1016/j.amjmed.2004.06.032.

  9. Суборцева И.Н., Колошейнова Т.И., Пустовая Е.И. и др. Истинная полицитемия: обзор литературы и собственные данные. Клиническая онкогематология. 2015;8(4):397–412. doi: 10.21320/2500-2139-2015-8-4-397-412.

    [Subortseva IN, Kolosheinova TI, Pustovaya EI, et al. Polycythemia Vera: Literature Review and Own Data. Clinical oncohematology. 2015;8(4):397–412. doi: 10.21320/2500-2139-2015-8-4-397-412. (In Russ)]

  10. Танашян М.М., Кузнецова П.И., Суборцева И.Н., Меликян А.Л. Клинические особенности течения цереброваскулярной патологии при Ph-негативных миелопролиферативных заболеваниях. Клиническая фармакология и терапия. 2016;25(5):54–7.

    [Tanashyan MM, Kuznetsova PI, Subortseva IN, Melikyan AL. Clinical characteristics of the course of cerebrovascular pathology in Ph-negative myeloproliferative diseases. Klinicheskaya farmakologiya i terapiya. 2016;25(5):54–7. (In Russ)]

  11. Танашян М.М., Кузнецова П.И., Суборцева И.Н. и др. Хроническая и острая цереброваскулярная патология при Ph-негативных миелопролиферативных заболеваниях. Гематология и трансфузиология. 2016;61(3):146–50. doi: 10.18821/0234-5730-2016-61-3-146-150.

    [Tanashyan MM, Kuznetsova PI, Subortseva IN, et al. Chronic and acute cerebrovascular pathology in patients with Ph-negative myeloproliferative diseases. Gematologiya i transfuziologiya. 2016;61(3):146–50. doi: 10.18821/0234-5730-2016-61-3-146-150. (In Russ)]

  12. Duangnapasatit B, Rattarittamrong E, Rattanathammethee T, et al. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Asian Pac J Cancer Prev. 2015;16(12):5013–8. doi: 10.7314/apjcp.2015.16.12.5013.

  13. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005;23(33):8520–30. doi: 10.1200/jco.2004.00.9316.

  14. Tanashyan MM, Kuznetsova PI, Shabalina AA, et al. Clinical characteristics of cerebrovascular pathology with patients suffering from Ph-negative myeloproliferative disease. Cerebrovasc Dis Extra. 2016;6(3):66–70. doi: 10.1159/000448597.

  15. Casini A, Fontana P, Lecompte T. Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management. J Thromb Haemost. 2013;11(7):1215–27. doi: 10.1111/jth.12265.

  16. Wolanskyj AP, Schwager SM, McClure RF, et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81(2):159–66. doi: 10.4065/81.2.159.

  17. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007;109(6):2310–3. doi: 10.1182/blood-2006-09-046342.

  18. Меликян А.Л., Суборцева И.Н., Ковригина А.М. и др. Диагностика латентной истинной полицитемии (взгляд клинициста). Терапевтический архив. 2016;88(7):25–30. doi: 10.17116/terarkh201688725-30.

    [Melikian AL, Subortseva IN, Kovrigina AM, et al. Diagnosis of latent polycythemia vera: A clinician’s opinion. Terapevticheskii arkhiv. 2016;88(7):25–30. doi: 10.17116/terarkh201688725-30. (In Russ)]

  19. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110(3):840–6. doi: 10.1182/blood-2006-12-064287.